Accretion Pharmaceuticals

Accretion Pharmaceuticals is a pre-clinical stage biotechnology company focused on developing next-generation small molecule therapeutics for oncology. Founded by Dr. Shaomeng Wang and based in Ann Arbor, Michigan, the company leverages advanced structure-based drug design to target historically undruggable protein-protein interactions. Its research efforts are centered on creating potent inhibitors and degraders for critical cancer targets, including Menin and MDM2. Accretion aims to address significant unmet medical needs in both hematologic malignancies and solid tumors through its innovative medicinal chemistry approach.